首页 > 最新文献

Journal of Nanjing Medical University最新文献

英文 中文
Clinical observations on the treatment of infantile hemangiomas with topical imiquimod 5% cream 5%咪喹莫特乳膏外用治疗婴幼儿血管瘤的临床观察
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60051-4
Zhengtuan Guo , Guowei Li , Quan Xu , Ya Gao , Peng Li , Xiansheng Zhang , Yitao Duan , Xinkui Guo , Baijun Zheng

Objective

To observe the efficacy and safety of topical imiquimod 5% cream in the treatment of uncomplicated infantile hemangiomas (IHs).

Methods

A total of 68 IHs were treated with topical imiquimod 5% cream. Among them, 36 were superficial, 22 were mixed, and 10 were deep. The size of IHs ranged from 1.0 cm, × 1.5 cm to an area of a whole forearm. All the hemangiomas were in a proliferative stage. Imiquimod was applied 3 times weekly in 44 patients and 5 times weekly in 24 patients for up to 36 weeks.

Results

All superficial IHs improved, and 18 achieved complete clinical resolution, 10 had excellent improvement, 5 showed moderate improvements, and 3 patients displayed minimal improvement. Two mixed IHs showed excellent improvement, 3 showed moderate improvement and 5 manifested minimal improvements. The remaining 12 mixed IHs and all deep IHs did not respond to the therapy. The total incidence of local adverse events was 58.82%(40/68), which included erythema or edema, local itching, incrustation or peeling, erosion or ulceration, although most of these were mild to moderate reactions and did not affect the treatment. Scarring occurred in 2 mixed IHs. No systemic side effects developed.

Conclusion

Imiquimod 5% cream may be a safe and effective alternative for the treatment of superficial IHs and some mixed IHs in which the superficial component predominates. An appropriate treatment duration for proliferative IHs treated with this therapy may be 24 weeks. Some local adverse events, such as crusting and erosion with possible scarring potential may occur and should be addressed by prompt, but temporary, discontinuation of the imiquimod. Topical imiquimod 5% cream can be prudently used in the treatment of IHs larger than 5.0 cm, × 5.0 cm in newborns and infants less than 6 months of age. To our knowledge, this is the largest IH group treated with imiquimod that has been reported in the literature to date.

目的观察5%咪喹莫特乳膏外用治疗婴幼儿无并发症血管瘤的疗效和安全性。方法采用5%咪喹莫特乳膏外用治疗68例his。其中浅表病变36例,混合性病变22例,深部病变10例。IHs的大小从1.0 cm × 1.5 cm到整个前臂的面积。所有血管瘤均处于增生期。44例患者每周应用3次咪喹莫特,24例患者每周应用5次咪喹莫特,疗程长达36周。结果所有患者均得到改善,18例患者临床完全缓解,10例患者改善良好,5例患者改善中等,3例患者改善轻微。2个混合his表现为良好改善,3个表现为中度改善,5个表现为轻微改善。其余12例混合性IHs和所有深部IHs对治疗无反应。局部不良事件的总发生率为58.82%(40/68),包括红斑或水肿、局部瘙痒、结痂或脱皮、糜烂或溃疡,但大多数为轻中度反应,不影响治疗。2例混合性IHs发生瘢痕形成。没有出现系统性副作用。结论5%咪喹莫特乳膏可作为治疗浅表性和部分以浅表性为主的混合性IHs的安全有效选择。使用这种疗法治疗增殖性IHs的适当治疗时间为24周。可能会发生一些局部不良事件,如结痂和糜烂,并可能形成疤痕,应通过迅速但暂时停用咪喹莫特来解决。5%咪喹莫特乳膏外用治疗大于5.0 cm、× 5.0 cm的新生儿和小于6个月的婴儿可谨慎使用。据我们所知,这是迄今为止文献中报道的使用咪喹莫特治疗的最大的IH组。
{"title":"Clinical observations on the treatment of infantile hemangiomas with topical imiquimod 5% cream","authors":"Zhengtuan Guo ,&nbsp;Guowei Li ,&nbsp;Quan Xu ,&nbsp;Ya Gao ,&nbsp;Peng Li ,&nbsp;Xiansheng Zhang ,&nbsp;Yitao Duan ,&nbsp;Xinkui Guo ,&nbsp;Baijun Zheng","doi":"10.1016/S1007-4376(09)60051-4","DOIUrl":"10.1016/S1007-4376(09)60051-4","url":null,"abstract":"<div><h3>Objective</h3><p>To observe the efficacy and safety of topical imiquimod 5% cream in the treatment of uncomplicated infantile hemangiomas (IHs).</p></div><div><h3>Methods</h3><p>A total of 68 IHs were treated with topical imiquimod 5% cream. Among them, 36 were superficial, 22 were mixed, and 10 were deep. The size of IHs ranged from 1.0 cm, × 1.5 cm to an area of a whole forearm. All the hemangiomas were in a proliferative stage. Imiquimod was applied 3 times weekly in 44 patients and 5 times weekly in 24 patients for up to 36 weeks.</p></div><div><h3>Results</h3><p>All superficial IHs improved, and 18 achieved complete clinical resolution, 10 had excellent improvement, 5 showed moderate improvements, and 3 patients displayed minimal improvement. Two mixed IHs showed excellent improvement, 3 showed moderate improvement and 5 manifested minimal improvements. The remaining 12 mixed IHs and all deep IHs did not respond to the therapy. The total incidence of local adverse events was 58.82%(40/68), which included erythema or edema, local itching, incrustation or peeling, erosion or ulceration, although most of these were mild to moderate reactions and did not affect the treatment. Scarring occurred in 2 mixed IHs. No systemic side effects developed.</p></div><div><h3>Conclusion</h3><p>Imiquimod 5% cream may be a safe and effective alternative for the treatment of superficial IHs and some mixed IHs in which the superficial component predominates. An appropriate treatment duration for proliferative IHs treated with this therapy may be 24 weeks. Some local adverse events, such as crusting and erosion with possible scarring potential may occur and should be addressed by prompt, but temporary, discontinuation of the imiquimod. Topical imiquimod 5% cream can be prudently used in the treatment of IHs larger than 5.0 cm, × 5.0 cm in newborns and infants less than 6 months of age. To our knowledge, this is the largest IH group treated with imiquimod that has been reported in the literature to date.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60051-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74277056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Isolation and characterization of cancer stem-like cells from MHCC97H Cell Lines MHCC97H细胞系肿瘤干细胞样细胞的分离与鉴定
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60054-X
Shanyong Yi , Kejun Nan , Aihua Yuan , Chuangxin Lu

Objective

To identify and isolate CD133 positive cancer stem-like cells (CD133+ cells) from the highly invasive human hepatocellular carcinoma cell line(MHCC97H), and examine their potential for clonogenicity and tumorigenicity.

Methods

CD133+ and CD133 cells were isolated from MHCC97H cell line by magnetic bead cell sorting(MACS), and the potentials of CD133+ cells for colony formation and tumorigenicity were evaluated by soft agar cloning and tumor formation following nude mice inoculation.

Results

CD133+ cells represent a minority(0.5-2.0%) of the tumor cell population with a greater colony-forming efficiency and greater tumor production ability. The colony-forming efficiency of CD133+ cells in soft agar was significantly higher than CD133 cells(36.8 ± 1.4 vs 12.9 ± 0.8, P < 0.05). After 6 weeks, 3/5 mice inoculated with 1 × 103 CD133+ cells, 4/5 with 1 × 104 CD133+ cells and 5/5 with 1 × 105 CD133+ cells developed detectable tumors at the injection site, while only one tumor was found in mice treated with same numbers of CD133 cells.

Conclusion

CD133 may be a hallmark of liver cancer stem cells (CSC) in human hepatocellular carcinoma(HCC), because the CD133+ cells identified and isolated with anti-CD133 labeled magnetic beads from MHCC97H cell line exhibit high potentials for clonogenicity and tumorigenicity. These CD133+ cells might contribute to hepatocarcinogenesis, as well as the growth and recurrence of human HCC, and therefore may be a useful target for anti-cancer therapy.

目的从高侵袭性人肝癌细胞系(MHCC97H)中鉴定和分离CD133阳性肿瘤干细胞样细胞(CD133+细胞),并研究其克隆性和致瘤性。方法采用磁珠细胞分选法(MACS)从MHCC97H细胞株中分离scd133 +和CD133−细胞,用软琼脂克隆和裸鼠接种后的成瘤性评价CD133+细胞的集落形成和致瘤性。结果scd133 +细胞占肿瘤细胞群的少数(0.5 ~ 2.0%),具有较高的集落形成效率和产瘤能力。CD133+细胞在软琼脂中的集落形成效率显著高于CD133−细胞(36.8±1.4 vs 12.9±0.8,P <0.05)。6周后,3/5接种1 × 103个CD133+细胞的小鼠、4/5接种1 × 104个CD133+细胞的小鼠和5/5接种1 × 105个CD133+细胞的小鼠在注射部位出现了可检测到的肿瘤,而相同数量CD133−细胞的小鼠只发现了一个肿瘤。结论CD133可能是人肝细胞癌(HCC)中肝癌干细胞(CSC)的标志,因为从MHCC97H细胞系中用抗CD133标记磁珠鉴定和分离的CD133+细胞具有高的克隆性和致瘤性。这些CD133+细胞可能有助于肝癌的发生,以及人类HCC的生长和复发,因此可能是抗癌治疗的有用靶点。
{"title":"Isolation and characterization of cancer stem-like cells from MHCC97H Cell Lines","authors":"Shanyong Yi ,&nbsp;Kejun Nan ,&nbsp;Aihua Yuan ,&nbsp;Chuangxin Lu","doi":"10.1016/S1007-4376(09)60054-X","DOIUrl":"10.1016/S1007-4376(09)60054-X","url":null,"abstract":"<div><h3>Objective</h3><p>To identify and isolate CD133 positive cancer stem-like cells (CD133<sup>+</sup> cells) from the highly invasive human hepatocellular carcinoma cell line(MHCC97H), and examine their potential for clonogenicity and tumorigenicity.</p></div><div><h3>Methods</h3><p>CD133<sup>+</sup> and CD133<sup>−</sup> cells were isolated from MHCC97H cell line by magnetic bead cell sorting(MACS), and the potentials of CD133<sup>+</sup> cells for colony formation and tumorigenicity were evaluated by soft agar cloning and tumor formation following nude mice inoculation.</p></div><div><h3>Results</h3><p>CD133<sup>+</sup> cells represent a minority(0.5-2.0%) of the tumor cell population with a greater colony-forming efficiency and greater tumor production ability. The colony-forming efficiency of CD133<sup>+</sup> cells in soft agar was significantly higher than CD133<sup>−</sup> cells(36.8 ± 1.4 vs 12.9 ± 0.8, <em>P</em> &lt; 0.05). After 6 weeks, 3/5 mice inoculated with 1 × 10<sup>3</sup> CD133<sup>+</sup> cells, 4/5 with 1 × 10<sup>4</sup> CD133<sup>+</sup> cells and 5/5 with 1 × 10<sup>5</sup> CD133<sup>+</sup> cells developed detectable tumors at the injection site, while only one tumor was found in mice treated with same numbers of CD133<sup>−</sup> cells.</p></div><div><h3>Conclusion</h3><p>CD133 may be a hallmark of liver cancer stem cells (CSC) in human hepatocellular carcinoma(HCC), because the CD133<sup>+</sup> cells identified and isolated with anti-CD133 labeled magnetic beads from MHCC97H cell line exhibit high potentials for clonogenicity and tumorigenicity. These CD133<sup>+</sup> cells might contribute to hepatocarcinogenesis, as well as the growth and recurrence of human HCC, and therefore may be a useful target for anti-cancer therapy.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60054-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86264852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A comparison of lightwand and laryngoscopic intubation techniques in patients undergoing laparoscopic cholecystectomy 腹腔镜胆囊切除术中光镜与喉镜插管技术的比较
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60056-3
Chenglan Xie, Congjin Ju, Jiawen Cheng, Xuejun Yan, Dengquan Guo

Objective

To assess the effects of lightwand and laryngoscopic intubation techniques in patients undergoing laparoscopic cholecystectomy (LC).

Methods

300 ASA physical status I and II patients, undergoing LC, were randomly assigned to two groups, with 150 cases in each group. Patients in the LS group underwent endotracheal intubation using a standard direct-suspension laryngoscopic technique. Patients in the LW group were intubated by using transillumination with a lightwand. Mean arterial pressure and heart rate were recorded before induction, and at 1, 3 and 5 min after intubation. The incidence and of sore throat, hoarseness, and dysphagia was assessed twenty-four hours after surgery.

Results

This study demonstrated no clinically significant difference in cardiovascular variables between the two techniques. Patients had a significantly lower incidence of sore throat, hoarseness, and dysphagia when the lightwand was used for intubation.

Conclusion

This study suggests that lightwand intubation may decrease the incidence of postoperative sore throat, hoarseness, and dysphagia, thereby potentially increasing satisfaction in surgical patients. Therefore, more frequent use of the lightwand is recommended for endotracheal intubation.

目的探讨光镜与喉镜插管技术在腹腔镜胆囊切除术中的应用效果。方法将300例ASA身体状态为I、II的LC患者随机分为两组,每组150例。LS组患者采用标准直接悬挂喉镜技术行气管插管。LW组采用光带透照插管。分别记录诱导前、插管后1、3、5 min的平均动脉压和心率。术后24小时评估喉痛、声音嘶哑和吞咽困难的发生率。结果本研究显示两种技术在心血管变量方面无临床显著差异。使用光导管插管时,患者喉咙痛、声音嘶哑、吞咽困难的发生率明显降低。结论光照插管可降低术后喉咙痛、声音嘶哑和吞咽困难的发生率,从而提高手术患者的满意度。因此,建议在气管插管时更频繁地使用光导管。
{"title":"A comparison of lightwand and laryngoscopic intubation techniques in patients undergoing laparoscopic cholecystectomy","authors":"Chenglan Xie,&nbsp;Congjin Ju,&nbsp;Jiawen Cheng,&nbsp;Xuejun Yan,&nbsp;Dengquan Guo","doi":"10.1016/S1007-4376(09)60056-3","DOIUrl":"10.1016/S1007-4376(09)60056-3","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the effects of lightwand and laryngoscopic intubation techniques in patients undergoing laparoscopic cholecystectomy (LC).</p></div><div><h3>Methods</h3><p>300 ASA physical status I and II patients, undergoing LC, were randomly assigned to two groups, with 150 cases in each group. Patients in the LS group underwent endotracheal intubation using a standard direct-suspension laryngoscopic technique. Patients in the LW group were intubated by using transillumination with a lightwand. Mean arterial pressure and heart rate were recorded before induction, and at 1, 3 and 5 min after intubation. The incidence and of sore throat, hoarseness, and dysphagia was assessed twenty-four hours after surgery.</p></div><div><h3>Results</h3><p>This study demonstrated no clinically significant difference in cardiovascular variables between the two techniques. Patients had a significantly lower incidence of sore throat, hoarseness, and dysphagia when the lightwand was used for intubation.</p></div><div><h3>Conclusion</h3><p>This study suggests that lightwand intubation may decrease the incidence of postoperative sore throat, hoarseness, and dysphagia, thereby potentially increasing satisfaction in surgical patients. Therefore, more frequent use of the lightwand is recommended for endotracheal intubation.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60056-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87600489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer CA19-9和CEA水平对胰腺癌诊断价值的评价
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60055-1
Zhenhua Ma, Qingyong Ma, Zheng Wang

Objective

The use of a combination of tumor markers may be an important tool in the early diagnosis of pancreatic cancer, which is the key to improving prognosis. The study aim was to investigate the diagnostic value of carbohydrate antigen 19-9(CA 19-9) and carcinoembryonic antigen(CEA) levels in patients with pancreatic cancer.

Methods

An immunoradiometric assay was used to homochronously measure the serum CA19-9 and CEA levels in 78 pancreatic cancer cases and 64 healthy examinees in hospital. The normal reference values were CA19-9(0-39 U/ml) and CEA(0-3.4 ng/ml).

Results

Mean serum CA19-9 and CEA levels in patients with pancreatic cancer(406.55 ± 60.18 U/ml, 12.43 ± 1.25 ng/ml) were significantly higher(P < 0.01) than those in healthy examinees(16.54 ± 1.95 U/ml, 2.37 ± 0.17 ng/ml). The sensitivity of the combined detection of CA19-9 and CEA (92.31%) was significantly higher(P < 0.05) than that of either marker alone (79.49%, 71.79%, respectively). In addition, the sensitivity to diagnose pancreatic cancer by detecting the serum CA19-9 and CEA levels was higher(P < 0.05) in stage, II B + III + IV(87.04%, 79.23%) than stage I + II, A(62.50%, 54.17%).

Conclusion

The combined detection of CA19-9 and CEA could overcome the deficiency of using single marker detection by improving the sensitivity to diagnose pancreatic cancer. At the same time, CA19-9 and CEA detection could be used to assess mesenteric artery invasion and the metastasis of lymphatics and distant organs in pancreatic cancer.

目的联合应用肿瘤标志物可能是早期诊断胰腺癌的重要工具,是改善预后的关键。目的探讨糖抗原19-9(CA 19-9)和癌胚抗原(CEA)水平对胰腺癌的诊断价值。方法采用免疫放射法同步测定78例胰腺癌患者和64例健康体检者血清CA19-9和CEA水平。正常参考值为CA19-9(0 ~ 39 U/ml)、CEA(0 ~ 3.4 ng/ml)。结果胰腺癌患者血清CA19-9、CEA平均水平(406.55±60.18 U/ml, 12.43±1.25 ng/ml)显著升高(P <0.01)高于健康体检者(16.54±1.95 U/ml, 2.37±0.17 ng/ml)。CA19-9与CEA联合检测的灵敏度(92.31%)显著高于对照组(P <0.05),分别为79.49%、71.79%。此外,检测血清CA19-9和CEA水平对胰腺癌诊断的敏感性较高(P <B + III + IV期(87.04%,79.23%)高于I + II, A期(62.50%,54.17%)。结论CA19-9与CEA联合检测可克服单一标志物检测的不足,提高胰腺癌的诊断敏感性。同时,CA19-9和CEA检测可用于评估胰腺癌肠系膜动脉浸润及淋巴和远端脏器转移情况。
{"title":"An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer","authors":"Zhenhua Ma,&nbsp;Qingyong Ma,&nbsp;Zheng Wang","doi":"10.1016/S1007-4376(09)60055-1","DOIUrl":"10.1016/S1007-4376(09)60055-1","url":null,"abstract":"<div><h3>Objective</h3><p>The use of a combination of tumor markers may be an important tool in the early diagnosis of pancreatic cancer, which is the key to improving prognosis. The study aim was to investigate the diagnostic value of carbohydrate antigen 19-9(CA 19-9) and carcinoembryonic antigen(CEA) levels in patients with pancreatic cancer.</p></div><div><h3>Methods</h3><p>An immunoradiometric assay was used to homochronously measure the serum CA19-9 and CEA levels in 78 pancreatic cancer cases and 64 healthy examinees in hospital. The normal reference values were CA19-9(0-39 U/ml) and CEA(0-3.4 ng/ml).</p></div><div><h3>Results</h3><p>Mean serum CA19-9 and CEA levels in patients with pancreatic cancer(406.55 ± 60.18 U/ml, 12.43 ± 1.25 ng/ml) were significantly higher(<em>P</em> &lt; 0.01) than those in healthy examinees(16.54 ± 1.95 U/ml, 2.37 ± 0.17 ng/ml). The sensitivity of the combined detection of CA19-9 and CEA (92.31%) was significantly higher(<em>P</em> &lt; 0.05) than that of either marker alone (79.49%, 71.79%, respectively). In addition, the sensitivity to diagnose pancreatic cancer by detecting the serum CA19-9 and CEA levels was higher(<em>P</em> &lt; 0.05) in stage, II B + III + IV(87.04%, 79.23%) than stage I + II, A(62.50%, 54.17%).</p></div><div><h3>Conclusion</h3><p>The combined detection of CA19-9 and CEA could overcome the deficiency of using single marker detection by improving the sensitivity to diagnose pancreatic cancer. At the same time, CA19-9 and CEA detection could be used to assess mesenteric artery invasion and the metastasis of lymphatics and distant organs in pancreatic cancer.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60055-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78810649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
HERG K+ channels expression in gastric cancers and analysis of its regulation in tumor cell proliferation and apoptosis 胃癌中HERG K+通道的表达及其对肿瘤细胞增殖和凋亡的调控分析
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60047-2
Qing Lü , Huiyu Li , Xiaoming Lu , Guobin Wang

Objective

To investigate the expression of herg1 gene in tumor tissues from gastric carcinomas and gastric carcinoma cell lines, and study the relationship between HERG K+ channel expressions and tumor cell proliferation and apoptosis.

Methods

RT-PCR and PCR assays were used to detect the expression of herg1 gene in 64 gastric carcinomas and the gastric cancer cell line SGC-7901. Blocking the HERG K+ channels was used to evaluate their effects on tumor cell proliferation and apoptosis.

Results

The statistically significant expression of herg1 gene was detected in all the gastric cancers and SGC-7901 cells, but not in normal tissues. The HERG K+ channel blocker, E-4031, increased the cell population in G0/G1(P < 0.05) and the number of apoptotic tumor cells(P < 0.05).

Conclusion

HERG K+ channels were expressed in all gastric carcinomas tested and these channels appear to modulate tumor cell proliferation and apoptosis.

目的观察胃癌及胃癌细胞系肿瘤组织中HERG - 1基因的表达,研究HERG - K+通道表达与肿瘤细胞增殖和凋亡的关系。方法采用srt -PCR和PCR法检测64例胃癌和胃癌细胞株SGC-7901中herg1基因的表达。阻断HERG K+通道对肿瘤细胞增殖和凋亡的影响。结果herg1基因在胃癌组织和SGC-7901细胞中均有表达,正常组织中无表达。HERG K+通道阻滞剂E-4031增加了G0/G1的细胞数量(P <0.05),肿瘤细胞凋亡数(P <0.05)。结论herg K+通道在所有胃癌组织中均有表达,并调节肿瘤细胞的增殖和凋亡。
{"title":"HERG K+ channels expression in gastric cancers and analysis of its regulation in tumor cell proliferation and apoptosis","authors":"Qing Lü ,&nbsp;Huiyu Li ,&nbsp;Xiaoming Lu ,&nbsp;Guobin Wang","doi":"10.1016/S1007-4376(09)60047-2","DOIUrl":"10.1016/S1007-4376(09)60047-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the expression of herg1 gene in tumor tissues from gastric carcinomas and gastric carcinoma cell lines, and study the relationship between HERG K+ channel expressions and tumor cell proliferation and apoptosis.</p></div><div><h3>Methods</h3><p>RT-PCR and PCR assays were used to detect the expression of herg1 gene in 64 gastric carcinomas and the gastric cancer cell line SGC-7901. Blocking the HERG K+ channels was used to evaluate their effects on tumor cell proliferation and apoptosis.</p></div><div><h3>Results</h3><p>The statistically significant expression of herg1 gene was detected in all the gastric cancers and SGC-7901 cells, but not in normal tissues. The HERG K+ channel blocker, E-4031, increased the cell population in G0/G1(<em>P</em> &lt; 0.05) and the number of apoptotic tumor cells(<em>P</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>HERG K+ channels were expressed in all gastric carcinomas tested and these channels appear to modulate tumor cell proliferation and apoptosis.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60047-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75656907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic ablation of Barrett's esophagus using the second generation argon plasma coagulation: a prospective randomized controlled trail 使用第二代氩等离子凝固的内镜下Barrett食管消融:一项前瞻性随机对照试验
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60052-6
Li Zhang , Lei Dong , Jia Liu , Xiaolan Lu , Jun Zhang

Objective

To investigate the efficacy and safety of the second generation argon plasma coagulation(VIO APC) in the ablation of Barrett's Esophagus.

Methods

A total of 35 patients with uncomplicated Barrett's esophagus entered into a prospective, randomized, unblinded study comparing the treatment VIO APC combined with a proton pump inhibiter with a proton pump inhibiter administered alone. VIO APC was performed at a power setting of 40W, and argon gas flow at 1.5-2.0 L/min, and, “forced” mode. Ablative treatment was repeated until either no Barrett's epithelium remained or a maximum of 5 treatment sessions occurred.

Results

In the ablation group, macroscopic complete ablation was achieved in 14 of 18 patients, and complete ablation confirmed by histology in 12 of 18 patients (P < 0.01). Buried glands were observed in 2 patients who had achieved macroscopic ablation. The Barrett's mucosa averaged a reduction of 65%(range 50-75%) in the remaining 4 patients. In the control group, only 2 patients had partial regression, median 30%(range 20-40%). In the ablation group, post-treatment 4 patients had transient retrosternal pain, and 3 patients had mild epigastric discomfort. One patient had a small hemorrhage during the procedure, which ceased after norepinephrine and thrombosin were administered through the endoscope biopsy channel. No adverse events were observed in the control group. During 11.8(4-15) months follow-up, patients who had achieved the complete ablation have no evidence of relapse of Barrett's esophagus.

Conclusion

VIO APC with a relatively low power setting can effectively ablate the Barrett's mucosa. No severe adverse events were observed. Long-term follow-up is needed to assess cancer prevention and the durability of the neo-squamous epithelium.

目的探讨第二代氩等离子凝固(VIO APC)治疗Barrett食管的有效性和安全性。方法对35例无并发症巴雷特食管患者进行前瞻性、随机、非盲研究,比较VIO APC联合质子泵抑制剂治疗与单独使用质子泵抑制剂治疗。VIO APC在功率为40W,氩气流量为1.5-2.0 L/min,“强制”模式下进行。反复消融治疗,直到没有巴雷特上皮或最多5次治疗。结果消融组18例患者中14例肉眼完全消融,12例组织学证实完全消融(P <0.01)。2例行肉眼消融术的患者可见腺体埋藏。其余4例患者巴雷特粘膜平均缩小65%(范围50-75%)。在对照组中,只有2例患者出现部分消退,中位数为30%(范围20-40%)。消融组治疗后4例患者出现一过性胸骨后疼痛,3例患者出现轻度上腹不适。一名患者在手术过程中出现小出血,在内窥镜活检通道给予去甲肾上腺素和凝血素后出血停止。对照组未见不良事件发生。在11.8(4-15)个月的随访中,完成完全消融的患者没有Barrett食管复发的迹象。结论vio APC在较低功率设置下可有效消融Barrett粘膜。未观察到严重的不良事件。需要长期随访来评估癌症预防和新鳞状上皮的持久性。
{"title":"Endoscopic ablation of Barrett's esophagus using the second generation argon plasma coagulation: a prospective randomized controlled trail","authors":"Li Zhang ,&nbsp;Lei Dong ,&nbsp;Jia Liu ,&nbsp;Xiaolan Lu ,&nbsp;Jun Zhang","doi":"10.1016/S1007-4376(09)60052-6","DOIUrl":"10.1016/S1007-4376(09)60052-6","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the efficacy and safety of the second generation argon plasma coagulation(VIO APC) in the ablation of Barrett's Esophagus.</p></div><div><h3>Methods</h3><p>A total of 35 patients with uncomplicated Barrett's esophagus entered into a prospective, randomized, unblinded study comparing the treatment VIO APC combined with a proton pump inhibiter with a proton pump inhibiter administered alone. VIO APC was performed at a power setting of 40W, and argon gas flow at 1.5-2.0 L/min, and, “forced” mode. Ablative treatment was repeated until either no Barrett's epithelium remained or a maximum of 5 treatment sessions occurred.</p></div><div><h3>Results</h3><p>In the ablation group, macroscopic complete ablation was achieved in 14 of 18 patients, and complete ablation confirmed by histology in 12 of 18 patients (<em>P</em> &lt; 0.01). Buried glands were observed in 2 patients who had achieved macroscopic ablation. The Barrett's mucosa averaged a reduction of 65%(range 50-75%) in the remaining 4 patients. In the control group, only 2 patients had partial regression, median 30%(range 20-40%). In the ablation group, post-treatment 4 patients had transient retrosternal pain, and 3 patients had mild epigastric discomfort. One patient had a small hemorrhage during the procedure, which ceased after norepinephrine and thrombosin were administered through the endoscope biopsy channel. No adverse events were observed in the control group. During 11.8(4-15) months follow-up, patients who had achieved the complete ablation have no evidence of relapse of Barrett's esophagus.</p></div><div><h3>Conclusion</h3><p>VIO APC with a relatively low power setting can effectively ablate the Barrett's mucosa. No severe adverse events were observed. Long-term follow-up is needed to assess cancer prevention and the durability of the neo-squamous epithelium.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60052-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73788946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Research progress on the treatment of spinal cord injury with cellular transplantation 细胞移植治疗脊髓损伤的研究进展
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60045-9
Cheng Lu , Qiang Shen

Spinal cord injury(SCI) is a severe trauma to the central nervous system(CNS). This article reviews recent advances in cellular transplantation to treat SCI. Transplanted cells can supply new neurons to replace injured ones, promote regeneration of axons and myelin sheath, modulate the inflammatory response, and thus promote recovery from traumatic injury of the CNS. Cellular transplantation is a promising potential method for the treatment of SCI.

脊髓损伤(SCI)是一种严重的中枢神经系统损伤。本文综述了细胞移植治疗脊髓损伤的最新进展。移植细胞可以提供新的神经元替代损伤的神经元,促进轴突和髓鞘的再生,调节炎症反应,从而促进中枢神经系统创伤性损伤后的恢复。细胞移植是一种很有潜力的治疗脊髓损伤的方法。
{"title":"Research progress on the treatment of spinal cord injury with cellular transplantation","authors":"Cheng Lu ,&nbsp;Qiang Shen","doi":"10.1016/S1007-4376(09)60045-9","DOIUrl":"10.1016/S1007-4376(09)60045-9","url":null,"abstract":"<div><p>Spinal cord injury(SCI) is a severe trauma to the central nervous system(CNS). This article reviews recent advances in cellular transplantation to treat SCI. Transplanted cells can supply new neurons to replace injured ones, promote regeneration of axons and myelin sheath, modulate the inflammatory response, and thus promote recovery from traumatic injury of the CNS. Cellular transplantation is a promising potential method for the treatment of SCI.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60045-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90256285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tako-tsubo cardiomyopathy
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60046-0
Yan Zhuang, Di Xu

Tako-tsubo cardiomyopathy(TC) is a recently described acute cardiac syndrome, which the latest cardiomyopathy classification of the European Society of Cardiology describes as an unclassified cardiomyopathy. TC mimics acute myocardial infarction(AMI) and is characterised by ischaemic chest symptoms, an elevated electrocardiogram ST-segment, and moderately increased levels of cardiac disease markers. However, patients with TC have no coronary angiogram-detectable or non-obstructive coronary arterial disease(CAD), and left ventriculography documents transient left apical and middle ventricular wall dysfunction. In this review, we describe TC and evaluate epidemiological, clinical and instrumental features, pathophysiological mechanisms, therapy and prognosis of this syndrome, with a view to raising awareness of the disease.

Tako-tsubo心肌病(TC)是最近发现的一种急性心脏综合征,欧洲心脏病学会最新的心肌病分类将其描述为一种未分类的心肌病。TC模拟急性心肌梗死(AMI),其特征是胸部缺血症状、心电图st段升高和心脏病标志物水平中度升高。然而,TC患者没有冠状动脉造影可检测到的或非阻塞性冠状动脉疾病(CAD),左心室造影记录了短暂的左心尖和中心壁功能障碍。在本文中,我们对TC进行了描述,并对其流行病学、临床和仪器特征、病理生理机制、治疗和预后进行了评价,以期提高人们对该疾病的认识。
{"title":"Tako-tsubo cardiomyopathy","authors":"Yan Zhuang,&nbsp;Di Xu","doi":"10.1016/S1007-4376(09)60046-0","DOIUrl":"10.1016/S1007-4376(09)60046-0","url":null,"abstract":"<div><p>Tako-tsubo cardiomyopathy(TC) is a recently described acute cardiac syndrome, which the latest cardiomyopathy classification of the European Society of Cardiology describes as an unclassified cardiomyopathy. TC mimics acute myocardial infarction(AMI) and is characterised by ischaemic chest symptoms, an elevated electrocardiogram ST-segment, and moderately increased levels of cardiac disease markers. However, patients with TC have no coronary angiogram-detectable or non-obstructive coronary arterial disease(CAD), and left ventriculography documents transient left apical and middle ventricular wall dysfunction. In this review, we describe TC and evaluate epidemiological, clinical and instrumental features, pathophysiological mechanisms, therapy and prognosis of this syndrome, with a view to raising awareness of the disease.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60046-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85642376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemical composition and antimicrobial activity of essential oil isolated from the cultured mycelia of Ganoderma japonicum 日本灵芝菌丝体挥发油化学成分及抑菌活性研究
Pub Date : 2009-05-01 DOI: 10.1016/S1007-4376(09)60049-6
Dandan Liu , Zheng Hu , Zhigang Liu , Bo Yang , Wenjuan Tu , Liang Li

Objective

To explore a new natural antibiotic.

Methods

The chemical composition of the essential oil from Ganoderma japonicum (G. japonicum) mycelia was analyzed by gas chromatography-mass spectrometry(GC-MS). The antimicrobial activity of the oil was evaluated against eighteen microorganisms, including bacteria, mildew and yeast by using a disc diffusion method. Furthermore, the minimum inhibitory concentrations(MIC) and the minimum bactericidal concentrations(MBC) of the essential oil against twelve clinical pathogens were determined.

Results

The main components of the oil were nerolidol, decadienal, linalool and benzyl alcohol. The antimicrobial results indicated that the oil inhibited all the tested bacterium, especially Methicillin-resistant Staphylococcus aureus (MRSA) in which the antibacterial activity exhibited a MBC of 1.03 mg/ml.

Conclusion

The essential oil of G. japonicum mycelium has significant inhibitory activity. It is a potential medicinal resource that can be used as a natural antibiotic.

目的探索一种新的天然抗生素。方法采用气相色谱-质谱联用技术对日本灵芝菌丝体挥发油的化学成分进行分析。采用圆盘扩散法对细菌、霉菌和酵母菌等18种微生物进行了抑菌活性评价。同时测定了精油对12种临床病原菌的最低抑菌浓度(MIC)和最低杀菌浓度(MBC)。结果精油的主要成分为神经樟醇、十烯二醛、芳樟醇和苯甲醇。结果表明,精油对所有细菌均有抑制作用,其中对耐甲氧西林金黄色葡萄球菌(MRSA)的抑菌活性最高,MBC为1.03 mg/ml。结论日本血吸虫菌丝体挥发油具有明显的抑菌活性。它是一种潜在的药用资源,可以用作天然抗生素。
{"title":"Chemical composition and antimicrobial activity of essential oil isolated from the cultured mycelia of Ganoderma japonicum","authors":"Dandan Liu ,&nbsp;Zheng Hu ,&nbsp;Zhigang Liu ,&nbsp;Bo Yang ,&nbsp;Wenjuan Tu ,&nbsp;Liang Li","doi":"10.1016/S1007-4376(09)60049-6","DOIUrl":"10.1016/S1007-4376(09)60049-6","url":null,"abstract":"<div><h3>Objective</h3><p>To explore a new natural antibiotic.</p></div><div><h3>Methods</h3><p>The chemical composition of the essential oil from <em>Ganoderma japonicum (G. japonicum)</em> mycelia was analyzed by gas chromatography-mass spectrometry(GC-MS). The antimicrobial activity of the oil was evaluated against eighteen microorganisms, including bacteria, mildew and yeast by using a disc diffusion method. Furthermore, the minimum inhibitory concentrations(MIC) and the minimum bactericidal concentrations(MBC) of the essential oil against twelve clinical pathogens were determined.</p></div><div><h3>Results</h3><p>The main components of the oil were nerolidol, decadienal, linalool and benzyl alcohol. The antimicrobial results indicated that the oil inhibited all the tested bacterium, especially <em>Methicillin-resistant Staphylococcus aureus</em> (MRSA) in which the antibacterial activity exhibited a MBC of 1.03 mg/ml.</p></div><div><h3>Conclusion</h3><p>The essential oil of <em>G. japonicum</em> mycelium has significant inhibitory activity. It is a potential medicinal resource that can be used as a natural antibiotic.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60049-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86291934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Microdilution inhibition test of Chinese herbs to assess their effect against clinical strains of Ureaplasma urealyticum in vitro 中药对临床解脲支原体体外抑菌效果的微稀释试验
Pub Date : 2009-03-01 DOI: 10.1016/S1007-4376(09)60043-5
Changtai Zhu, Chunlei Dong, Yinze Kong, Lingxia Liu, Qingsi Wu, Yuyou Yao
{"title":"Microdilution inhibition test of Chinese herbs to assess their effect against clinical strains of Ureaplasma urealyticum in vitro","authors":"Changtai Zhu, Chunlei Dong, Yinze Kong, Lingxia Liu, Qingsi Wu, Yuyou Yao","doi":"10.1016/S1007-4376(09)60043-5","DOIUrl":"https://doi.org/10.1016/S1007-4376(09)60043-5","url":null,"abstract":"","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80345112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Journal of Nanjing Medical University
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1